BELLEVILLE, ON, June 13, 2014 /PRNewswire/ - Bioniche Life Sciences Inc. (TSX:
BNC) - ("Bioniche" or the "Company"), a clinical stage biotechnology
company whose anchor product is a Phase III treatment for
non-muscle-invasive bladder cancer, today announced that Dr. Michael
Berendt, Chief Executive Officer and Chief Scientist of Bioniche Life
Sciences Inc., will present a corporate update at the Bloom Burton &
Co. Healthcare Investor Conference at the Toronto Board of Trade on
June 18, 2014 at 3:30 P.M. EDT in Toronto. Bioniche's corporate
presentation will be available on the Company's website at www.bioniche.com following the presentation.
Bloom Burton's third annual healthcare investor conference features
Canada's premier publicly-traded and venture-backed private companies.
The event will attract Canadian, U.S. and European investors who are
interested in the latest developments in Canadian healthcare companies.
About Bioniche Life Sciences Inc.
Bioniche Life Sciences Inc. is a clinical stage Canadian
biopharmaceutical company focused on the discovery, development,
manufacturing, and marketing of proprietary and innovative therapies
for the global human health market. The Company's primary goal is to
develop and commercialize products that advance human health and
increase shareholder value. For more information, please visit www.Bioniche.com.
Except for historical information, this news release may contain
forward-looking statements that reflect the Company's current
expectation regarding future events. These forward-looking statements
involve risk and uncertainties, which may cause, but are not limited
to, changing market conditions, the successful and timely completion of
clinical studies, the establishment of corporate alliances, the impact
of competitive products and pricing, new product development,
uncertainties related to the regulatory approval process, and other
risks detailed from time to time in the Company's ongoing quarterly and
SOURCE Bioniche Life Sciences Inc.